Xenon Pharmaceuticals Inc.

Novartis Ag

Novartis Pharma Gmbh

Rajender Kamboj

Vishnumurthy Kodumuru

Shaoyi Sun

Shifeng Liu

Serguei Sviridov

Zaihui Zhang

Jianmin Fu

Vandna Raina

Nagasree Chakka

Duanjie Hou

Heinz W Gschwend

Sultan Chowdhury

Melwyn A Abreo

Michael D Winther

Wenbao Li

Mehran Seid Bagherzadeh

Mikhail A Chafeev

Chi Tu

Natalia Pokrovskaia

Natalie Alysia Dales

Mark W Holladay

Daniel F Harvey

Mikhail Kondratenko

Robert Fraser

Jianyu Sun

Yigal Paul Goldberg

Jian-Min Fu

Julia Fonarev

Tom Hsieh

Sengen Sun

Cindy J Hudson

Kashinath Sadalapure

Mehran Bagherzadeh

Shifeng Lui

Heinz Gschwend

Michael Winther

Sun Shaoyi

Kashinath Sadalupure

Mikhail Chafev

Jian-min Fu

Mikhail A Kondratenko

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I), where V, W, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Aminothiazole derivatives as human stearoyl-CoA desaturase inhibitors

Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.

Juvenile hemochromatosis gene (HFE2A) cleavage products and uses thereof

The present invention provides heterocyclic derivatives that modulate the activity of stearoyl-CoA desaturase. Methods of using such derivatives to modulate the activity of stearoyl-CoA desaturase and pharmaceutical compositions comprising such derivatives are also encompassed.

Organic compounds

This invention is directed to methods of using spiro-oxindole compounds of formula (I): wherein k, j, Q, R, R, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, for the treatment and/or prevention of hypercholesterolemia, benign prostatic hyperplasia, pruritis and cancer. 

Use of spiro-oxindole compounds as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I): 

Pyridyl derivatives and their use as therapeutic agents

SCD1 inhibitors triazole and tetrazole compounds

Isolated fragments of the HFE2A protein able to bind and modulate HFE2A and other proteins, such as hepcidin, involved in the iron metabolism pathway are disclosed, such fragments being of molecular weight of approximately 7 kDa to 43 kDa. Also disclosed are corresponding isolated polynucleotides encoding the fragments of the HFE2A protein. The invention includes derivatives and analogs of the polypeptide fragments of HFE2A, along with compositions of these, that are functionally active, i.e. capable of interacting with the HFE2A, as well as methods of production of the HFE2A cleavage products, derivatives and analogs, e.g. by recombinant means. Methods for identifying modulators of HFE2A, comprising contacting a test compound with HFE2A and determining a change in HFE2A activity due to the compound, are provided. Also taught are methods of diagnosing an animal afflicted with or at risk of developing a disease of iron metabolism comprising determining a change in the level, amount or activity of a fragment of an HFE2A obtained in a sample from said animal relative to the level, amount or activity of a fragment of an HFE2A obtained in a control sample from an unaffected animal, wherein a change identifies said individual as being affect by or at risk of developing a disease of iron metabolism. Methods for treating and/or preventing a disorder in animals comprising administering to an animal afflicted therewith, or at risk of developing said disorder, a therapeutically effective amount of an HFE2A modulator are provided.

Heterocyclic inhibitors of stearoyl-CoA desaturase

A method of treating an SCD-mediated disease or condition in a mammal, preferably a human, includes administering to a mammal a compound of formula (I): 

Pyridazine derivatives and their use as inhibitors of stearoyl-CoA desaturase-1 activity in a mammal

This invention is directed to spiro-oxindole compounds of formula (I): wherein k, j, Q, RR, R, R, R, R, R, R, and Rare as defined herein, as a stereoisomer, enantiomer, tautomer thereof or mixtures thereof; or a pharmaceutically acceptable salt, solvate or prodrug thereof, which are useful for the treatment and/or prevention of sodium channel-mediated diseases or conditions, such as pain. Pharmaceutical compositions comprising the compounds and methods of preparing and using the compounds are also disclosed.

Spiro-oxindole compounds and their uses as therapeutic agents

Methods of treating an SCD-mediated disease or condition in a mammal, preferably a human, are disclosed, wherein the methods comprise administering to a mammal in need thereof a compound of formula (I) where x, y, J, K, W, V, R, R, R, R, R, R, R, R, Rand Rare defined herein. Pharmaceutical compositions comprising the compounds of formula (I) are also disclosed. 

Heterocyclic derivatives and their use as stearoyl-CoA desaturase inhibitors

Heterocyclic compounds suitable for the treatment of diseases related to elevated lipid levels

Piperazine derivatives as stearoyl-coa desaturase inhibitors and their use as therapeutic agents

Growing community of inventors

Burnaby, Canada

Rajender Kamboj